The introduction of tyrosine kinase inhibitors (TKI) and mTOR targeted therapies in combination with immunotherapies has been a major step forward in the treatment of renal cell carcinoma [1,3]. This evidence concerns the gene MTOR and hereditary clear cell renal cell carcinoma.